ALPS Medical Breakthroughs ETF(SBIO · ETF)
ETF quote, holdings, sector allocation, technicals, and options analytics.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
Snapshot
$52.94
- 52-Week Range
- $29.33 – $57.77
- YTD
- +5.53%
- IV Rank (30D)
- 25.23
- Straddle Price
- $4.12
- P/C Vol Ratio
- 0.53
Info
ALPS Medical Breakthroughs ETF (SBIO) ETF
- Exchange
- ARCX
- Inception
- 2014-12-30
- Has Options
- Yes
ETF Profile
holdings as of 2026-11-30
Holdings
92
AUM
$138.0M
Provider
Unknown
Inception
2014-12-30
Exchange
ARCX
Data As Of
2026-11-30
Expense Ratio
—
Dividend Yield
—
Distribution
Annual
Recent distributions
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2024-12-19 | 2024-12-26 | $1.1735 | CD |
| 2023-12-21 | 2023-12-27 | $0.0711 | CD |
Asset Allocation
Top Holdings
top 50 of 92 holdings
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| KYMR | Kymera Therapeutics Inc | 4.66% | Equity (common) | US |
| CELC | Celcuity Inc | 3.34% | Equity (common) | US |
| ALKS | Alkermes Plc | 3.21% | Equity (common) | IE |
| CGON | Cg Oncology Inc | 3.06% | Equity (common) | US |
| MIRM | Mirum Pharmaceuticals Inc | 3.06% | Equity (common) | US |
| FOLD | Amicus Therapeutics Inc | 2.86% | Equity (common) | US |
| ACAD | Acadia Pharmaceuticals Inc | 2.68% | Equity (common) | US |
| NAMS | Newamsterdam Pharma Co Nv | 2.60% | Equity (common) | NL |
| CRNX | Crinetics Pharmaceuticals Inc | 2.52% | Equity (common) | US |
| APGE | Apogee Therapeutics Inc | 2.48% | Equity (common) | US |
| VKTX | Viking Therapeutics Inc | 2.47% | Equity (common) | US |
| GPCR | Structure Therapeutics Inc | 2.47% | Equity (common) | KY |
| XENE | Xenon Pharmaceuticals Inc | 2.16% | Equity (common) | CA |
| SYRE | Spyre Therapeutics Inc | 2.15% | Equity (common) | US |
| EWTX | Edgewise Therapeutics Inc | 2.08% | Equity (common) | US |
| TARS | Tarsus Pharmaceuticals Inc | 2.07% | Equity (common) | US |
| DNLI | Denali Therapeutics Inc | 2.01% | Equity (common) | US |
| IDYA | Ideaya Biosciences Inc | 1.82% | Equity (common) | US |
| TVTX | Travere Therapeutics Inc | 1.72% | Equity (common) | US |
| APLS | Apellis Pharmaceuticals Inc | 1.71% | Equity (common) | US |
| VERA | Vera Therapeutics Inc | 1.68% | Equity (common) | US |
| IRON | Disc Medicine Inc | 1.62% | Equity (common) | US |
| DNTH | Dianthus Therapeutics Inc | 1.53% | Equity (common) | US |
| MLYS | Mineralys Therapeutics Inc | 1.50% | Equity (common) | US |
| GLPG | Galapagos Nv | 1.42% | Equity (common) | BE |
| MAZE | Maze Therapeutics Inc | 1.42% | Equity (common) | US |
| ZLAB | Zai Lab Ltd | 1.39% | Equity (common) | KY |
| STOK | Stoke Therapeutics Inc | 1.34% | Equity (common) | US |
| NUVB | Nuvation Bio Inc | 1.31% | Equity (common) | US |
| CLDX | Celldex Therapeutics Inc | 1.29% | Equity (common) | US |
| OLMA | Olema Pharmaceuticals Inc | 1.23% | Equity (common) | US |
| PHVS | Pharvaris Nv | 1.17% | Equity (common) | NL |
| VCEL | Vericel Corp | 1.17% | Equity (common) | US |
| RLAY | Relay Therapeutics Inc | 1.15% | Equity (common) | US |
| TYRA | Tyra Biosciences Inc | 1.15% | Equity (common) | US |
| AGIO | Agios Pharmaceuticals Inc | 1.14% | Equity (common) | US |
| SRPT | Sarepta Therapeutics Inc | 1.13% | Equity (common) | US |
| OCS | Oculis Holding Ag | 1.09% | Equity (common) | CH |
| AMLX | Amylyx Pharmaceuticals Inc | 1.08% | Equity (common) | US |
| ORKA | Oruka Therapeutics Inc | 1.08% | Equity (common) | US |
| NVAX | Novavax Inc | 1.06% | Equity (common) | US |
| IMCR | Immunocore Holdings Plc | 1.05% | Equity (common) | GB |
| SION | Sionna Therapeutics Inc | 1.05% | Equity (common) | US |
| PVLA | Palvella Therapeutics Inc | 1.03% | Equity (common) | US |
| MBX | Mbx Biosciences Inc | 0.94% | Equity (common) | US |
| ZBIO | Zenas Biopharma Inc | 0.91% | Equity (common) | US |
| IMTX | Immatics Nv | 0.90% | Equity (common) | NL |
| RAPP | Rapport Therapeutics Inc | 0.89% | Equity (common) | US |
| CRVS | Corvus Pharmaceuticals Inc | 0.88% | Equity (common) | US |
| TSHA | Taysha Gene Therapies Inc | 0.80% | Equity (common) | US |
Geographic Breakdown
Fund Holdings
ALPS Medical Breakthroughs ETF ·
NPORT-P period 2026-11-30
(filed 2026-04-29)
Net assets:
$138M
· 92 total positions
· equity 100.00%
· non-equity 0.04%
| # | Symbol | Issuer | Weight | Value |
|---|---|---|---|---|
| 1 | Kymera Therapeutics, Inc. | Kymera Therapeutics Inc | 4.66% | $6.4M |
| 2 | Celcuity, Inc. | Celcuity Inc | 3.34% | $4.6M |
| 3 | Alkermes PLC | Alkermes Plc | 3.21% | $4.4M |
| 4 | CG oncology, Inc. | Cg Oncology Inc | 3.06% | $4.2M |
| 5 | Mirum Pharmaceuticals, Inc. | Mirum Pharmaceuticals Inc | 3.06% | $4.2M |
| 6 | Amicus Therapeutics, Inc. | Amicus Therapeutics Inc | 2.86% | $4.0M |
| 7 | ACADIA Pharmaceuticals, Inc. | Acadia Pharmaceuticals Inc | 2.68% | $3.7M |
| 8 | Newamsterdam Pharma Co. NV | Newamsterdam Pharma Co Nv | 2.60% | $3.6M |
| 9 | Crinetics Pharmaceuticals, Inc. | Crinetics Pharmaceuticals Inc | 2.52% | $3.5M |
| 10 | Apogee Therapeutics, Inc. | Apogee Therapeutics Inc | 2.48% | $3.4M |
| 11 | Viking Therapeutics, Inc. | Viking Therapeutics Inc | 2.47% | $3.4M |
| 12 | Structure Therapeutics, Inc. | Structure Therapeutics Inc | 2.47% | $3.4M |
| 13 | Xenon Pharmaceuticals, Inc. | Xenon Pharmaceuticals Inc | 2.16% | $3.0M |
| 14 | Spyre Therapeutics, Inc. | Spyre Therapeutics Inc | 2.15% | $3.0M |
| 15 | Edgewise Therapeutics, Inc. | Edgewise Therapeutics Inc | 2.08% | $2.9M |
| 16 | Tarsus Pharmaceuticals, Inc. | Tarsus Pharmaceuticals Inc | 2.07% | $2.9M |
| 17 | Denali Therapeutics, Inc. | Denali Therapeutics Inc | 2.01% | $2.8M |
| 18 | Ideaya Biosciences, Inc. | Ideaya Biosciences Inc | 1.82% | $2.5M |
| 19 | Travere Therapeutics, Inc. | Travere Therapeutics Inc | 1.72% | $2.4M |
| 20 | Apellis Pharmaceuticals, Inc. | Apellis Pharmaceuticals Inc | 1.71% | $2.4M |
| 21 | Vera Therapeutics, Inc. | Vera Therapeutics Inc | 1.68% | $2.3M |
| 22 | Disc Medicine, Inc. | Disc Medicine Inc | 1.62% | $2.2M |
| 23 | Dianthus Therapeutics, Inc. | Dianthus Therapeutics Inc | 1.53% | $2.1M |
| 24 | Mineralys Therapeutics, Inc. | Mineralys Therapeutics Inc | 1.50% | $2.1M |
| 25 | Galapagos NV | Galapagos Nv | 1.42% | $2.0M |
Showing top 25 of 85 equity holdings.
Price History
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -1.59% | 6 |
| Feb | -1.69% | 6 |
| Mar | -2.95% | 6 |
| Apr | +0.47% | 6 |
| May | -0.68% | 6 |
| Jun | +2.11% | 6 |
| Jul | +4.12% | 5 |
| Aug | +2.96% | 5 |
| Sep | -3.43% | 5 |
| Oct | +1.73% | 5 |
| Nov | +1.90% | 5 |
| Dec | +3.04% | 5 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $52.30
SMA 50: $53.92
SMA 200: $48.45
Current: $52.76
EMA 12: $51.96
EMA 26: $52.60
MACD: -0.6374 | Signal: -0.0015
BEARISH
ADX (14): 12.75
RANGE
+DI: 25.42
−DI: 24.34
Momentum Oscillators
RSI (14): 50.53
NEUTRAL
Stoch %K: 39.42
Stoch %D: 29.42
Williams %R: -40.15
Volume & Volatility
BB Upper: $54.99
BB Lower: $49.60
NEUTRAL
OBV: 254,158
Vol SMA 20: 23,831
Vol ROC: -43.39%
ATR: $1.54
True Range: $1.51
HV 20: 38.7%
HV 30: 34.1%
HV 60: 34.9%
Data Summary
Data Points: 500
Last Updated: 2026-06-12T21:15:18.386000
Date Range: 2024-06-14T00:00:00 – 2026-06-12T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
Options Activity
- IV Rank (30D)
- 25.23
- IV Rank (7D)
- 46.01
- Avg IV
- 49.9%
- Straddle (30D)
- $4.12
- Straddle (7D)
- $2.17
- P/C Volume
- 0.53
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Volatility Surface
Enter a ticker to render the implied volatility surface.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 1.19
- Correlation (SPY)
- 49.2%
- R²
- 0.24
- Ann. Volatility
- 29.8%
- SPY Volatility
- 12.3%
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Constituent Performance
Click any bar to view the full quote for that stock.
Constituents
| Symbol | Price | 1 Day | 1 Week | 1 Month |
|---|